PT  - JOURNAL ARTICLE
AU  - Haolin Liu
AU  - Pengcheng Wei
AU  - Qianqian Zhang
AU  - Zhongzhou Chen
AU  - Katja Aviszus
AU  - Walter Downing
AU  - Shelley Peterson
AU  - Lyndon Reynoso
AU  - Gregory P. Downey
AU  - Stephen K. Frankel
AU  - John Kappler
AU  - Philippa Marrack
AU  - Gongyi Zhang
TI  - 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab <em>in vitro</em>
AID  - 10.1101/2021.02.16.431305
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.02.16.431305
4099  - http://biorxiv.org/content/early/2021/02/16/2021.02.16.431305.short
4100  - http://biorxiv.org/content/early/2021/02/16/2021.02.16.431305.full
AB  - We generated several versions of the receptor binding domain (RBD) of the Spike protein with mutations existing within newly emerging variants from South Africa and Brazil. We found that the mutant RBD with K417N, E484K, and N501Y exchanges has higher binding affinity to the human receptor compared to the wildtype RBD. This mutated version of RBD also completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.Competing Interest StatementH.L. is partially supported by NB Life Laboratory LLC, G.Z. holds equity at NB Life Laboratory LLC. We do not have any financial relation with Pfizer-BioNTech, Moderna, Eli Lilly, or Regeneron.